On Wednesday, the FDA gave the green light to a new antibiotic that could change how complicated urinary tract infections are treated. GSK plc (GSK) and Spero Therapeutics (SPRO) announced the approval of Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated UTIs (cUTIs), including pyelonephritis—a kidney infection. It's the first oral carbapenem ever approved for this patient population.

Carbapenems are a powerful class of antibiotics often reserved for severe or drug-resistant infections. But until now, they've only been available intravenously, meaning patients had to be in a hospital to get them. Utebzi changes that: it's a pill that can be taken at home, potentially freeing up hospital beds and cutting healthcare costs.

The approval is based on GSK's global licensing deal with Spero, which covers most of the world except parts of Asia. The companies note that cUTIs affect more than 3 million people in the U.S. each year. Treatment failure occurs in up to 34% of patients, and infections caused by multidrug-resistant pathogens add over $6 billion in annual healthcare costs. An oral option could make a real dent in those numbers.

The FDA's decision was backed by the Phase 3 PIVOT-PO trial, which compared Utebzi to intravenous imipenem-cilastatin in hospitalized patients. The oral drug achieved an overall success rate of 58.5%, versus 60.2% for the IV treatment—a difference of just 1.3 percentage points, well within the non-inferiority margin. The adjusted treatment difference was minus 1.3%, with a 95% confidence interval of minus 7.5% to 4.8%.

GSK says Utebzi should be available to U.S. patients by the end of 2026. The development was partly funded by the Biomedical Advanced Research and Development Authority (BARDA).

As for the market reaction: GSK shares ticked up 0.64% to $52.55, while Spero shares dropped 18.41% to $2.87 at the time of publication. The Spero slide might reflect profit-taking or disappointment that the approval didn't include a broader label, but the long-term potential remains significant.

This is a big deal for antibiotic development, which has long been underfunded and underappreciated. An oral carbapenem could be a valuable tool in the fight against antimicrobial resistance—and a nice revenue stream for GSK and Spero.